|Bid||0.00 x 87300|
|Ask||0.00 x 10000|
|Day's Range||70.68 - 71.02|
|52 Week Range||65.89 - 77.69|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Celgene could comfortably spend $11 billion to acquire Juno, an analyst said Wednesday after rumors circulated that the two biotechs could be in merger talks.
Novartis has been granted fast-track reviews of its cell therapy Kymriah for blood cancers in the United States and Europe, the Swiss drugmaker said on Wednesday, as it seeks to expand the pool of patients eligible for the costly treatment. Kymriah, already approved for treatment of children and young adults with r/r B-cell acute lymphoblastic leukemia (ALL), will now get speedy scrutiny by the U.S. Food and Drug Administration for use against relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL) in adults, the company said in a statement. In addition, the European Medicines Agency granted an accelerated assessment for Kymriah in children and young adults with ALL.
Novartis (NVS) Biologics License Application (BLA) for the proposed biosimilar of blockbuster drug Humira was accepted by the FDA under the 351 (k) pathway.
On the heels of collaborations with Bristol-Myers Squibb (BMY) and Allergan (AGN), Chapel Hill-based clinical data company Target PharmaSolutions’ latest collaboration is with Novartis (NVS). Novartis will collaborate with Target on its NASH study, focused on patients with nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH).
Novartis (NVS) announced the initiation of a trial on the biosimilar version of Cosentyx which will compare the drug to its proposed biosimilar for the treatment of ankylosing spondylitis.
Merck's Keytruda receives approval in Japan for bladder cancer. Seattle Genetics' Adcetris and Novartis' Kisqali get regulatory status updates from the FDA.
Juno's year-long rally came to an abrupt halt last month on concerns that it won't be able to catch up to the leaders in CAR-T.
Novartis (NVS) announces that the FDA has granted the second breakthrough designation to breast cancer drug, Kisqali, for the initial endocrine-based treatment of pre- or peri-menopausal women with HR+/HER2- advanced or metastatic breast cancer.
Advair, the world’s top-selling respiratory drug, will probably face generic competition in the U.S. beginning in 2018. It’s the biggest moneymaker for United Kingdom-based GlaxoSmithKline , whose earnings estimates have been sliding, and whose shares have tumbled since the summer. To see why, look back to Pfizer (PFE) seven years ago, on the eve of Lipitor’s patent expiration.
Although it's been a relatively slow week, two acquisition deals were announced with Roche (RHHBY) saying it will acquire Ignyta while Mallinckrodt will buy Sucampo.
ZURICH, Dec 28 (Reuters) - The Swiss blue-chip SMI was seen opening 0.2 percent higher at 9,452 points on Thursday, according to premarket indications by bank Julius Baer . The following are some of the ...
Dec 28 (Reuters) - China Pioneer Pharma Holdings Ltd : * CO ENTERED AGREEMENT WITH ALCON AND AFFILIATE BEIJING NOVARTIS PHARMACEUTICAL CO FOR SALE OF OPHTHALMIC PHARMACEUTICAL PRODUCTS * PARTIES AGREE ...
Dec 28 (Reuters) - Luye Pharma Group Ltd: * COURT OF APPEAL FOR DISTRICT OF MUNICH, GERMANY DISMISSES APPEAL FROM NOVARTIS AG AS CLAIMANT IN PATENT INFRINGEMENT LAWSUIT * PATENT INFRINGEMENT LAWSUIT ON ...
Allergan Inc said on Friday that it had lost its appeal in a patent battle with Novartis AG over its Sandoz division's rival version of Allergan's Combigan eye drug and said it would file a petition to for a rehearing of the case. Allergan said the U.S. Court of Appeals for the Federal Circuit affirmed the U.S. District Court for the Eastern District of Texas' earlier decision that the Sandoz rival did not infringe two of Allergan's patents and reversed a decision on a third patent in favor of Novartis.
SAN FRANCISCO (AP) — A sharply divided California Supreme Court ruled Thursday that pharmaceutical companies can be held liable for warning labels on generic versions of drugs they once made even after they've sold the drugs to other companies and stopped manufacturing them.
California's top court on Thursday opened the door for consumers to sue Novartis AG and other makers of brand-name pharmaceutical products over injuries blamed on generic versions of the drugs manufactured by other companies. The California Supreme Court's ruling broke with decisions nationally to the contrary and created exposure for brand-name drugmakers who could be sued in the state for failing to warn users about the risks of cheaper, generic versions of their drugs. Leslie Brueckner, the plaintiffs' lawyer, said the decision was the only one currently by a state's top court to favor consumers of generic drugs, who legally cannot sue generic drugmakers for not warning about their products' risks.
Want to cash in on the pharmaceutical boom? Generic drugs add to the arguments for giving Pfizer, Novartis and Mylan a closer look.
Novartis (NVS) is at a transitional stage as the CEO of its oncology segment will step down by the end of year. The company's CEO is also going to step next year.
Ultragenyx Pharmaceutical Inc. has agreed to sell a Food and Drug Administration-issued priority review voucher to Novartis AG for $130 million, the company said on Monday. Ultragenyx shares rose 3.4% ...